Chiquita Brooks-LaSure (Photo by Caroline Brehman/CQ Roll Call via AP Images)
Just the idea of Aduhelm's long-term financial risks has CMS jacking up premiums, deductibles for 2022
Although sales of Biogen’s expensive new Alzheimer’s drug have been anemic since the approval in June, the prospect of CMS eventually paying for it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
